Quidel product launch sets up for 2015 growth, says Canaccord Canaccord said Quidel is in the midst of a major new product launch which sets up 2015 for solid 20% growth. The firm trimmed its Q2 estimates but believes the long term thesis remains intact and keeps its Buy rating and $28 price target on Quidel.
News For QDEL From The Last 14 Days
Check below for free stories on QDEL the last two weeks.
Life Sciences highlights this week at Canaccord Canaccord highlighted six diagnostic names that report this week and recommends buying Top Pick IDEXX (IDXX) into the print given strong recurring razor/razorblade sales and consistent organic growth. The analyst expects Hold rated Quest Diagnostics (DGX) to report upside to Street estimates of $1.06/$1.882B, Quidel (QDEL) to have an uneventful report, Exact Sciences (EXAS) to provide an update on numerous catalysts near-term and Abaxis (ABAX) to report earnings below consensus. Lastly, the firm is cautious on Meridian Bioscience (VIVO) following a competitor report last week.